VivoSeq
Oncology

Retroperitoneal Sarcoma

6

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Retroperitoneal Sarcoma is an early-stage landscape with 6 programs across 4 companies. The most active players are Eli Lilly, TLC Biopharmaceuticals, Inc., Novartis. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

0/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1T

TLC Biopharmaceuticals, Inc.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2Pfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Active, not recruiting1 · 14%
Unknown status1 · 14%
Enrolling by invitation1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT04031677·250 enrolled
Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma
Recruiting·UUniversity of Washington·Phase 1·NCT06025747·18 enrolled
First-in-Human Phase I and II Study to Determine Safety and Efficacy of Proton-Spatially Fractionated Radiotherapy (P-SFRT) in Retroperitoneal Soft Tissue Sarcoma
Recruiting·NNorthwestern University·Preclinical·NCT06327477·28 enrolled
Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ("RESQU-SARC" Trial)
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04189783·113 enrolled
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
Enrolling by invitation·PPeking University International Hospital·Phase 4·NCT05844813·102 enrolled
Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas
Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01048723·2 enrolled
Radical Resection and HIPEC for Recurrent Retroperitoneal Sarcoma
Unknown status·National Cancer Centre, Singapore·N/A·NCT03792867·5 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)